Research programme: Leishmaniasis vaccine - Etna Biotech/NIAID

Drug Profile

Research programme: Leishmaniasis vaccine - Etna Biotech/NIAID

Alternative Names: Visceral leishmaniasis vaccine - Etna Biotech/NIAID; VL vaccine - Etna Biotech/NIAID

Latest Information Update: 08 Jun 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Etna Biotech; National Institute of Allergy and Infectious Diseases
  • Class Leishmaniasis vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Research Visceral leishmaniasis

Most Recent Events

  • 23 Apr 2015 Etna Biotech and NIAID agree to co-develop vaccine in USA for Leishmaniasis (Prevention)
  • 23 Apr 2015 Early research in Visceral leishmaniasis (Prevention) in Italy (unspecified route)
  • 23 Apr 2015 Early research in Visceral leishmaniasis (Prevention) in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top